Dna Group (T.R.) Past Earnings Performance
Past criteria checks 0/6
Dna Group (T.R.) has been growing earnings at an average annual rate of 22.5%, while the Electronic industry saw earnings growing at 35.7% annually. Revenues have been growing at an average rate of 81.9% per year.
Key information
22.5%
Earnings growth rate
48.9%
EPS growth rate
| Electronic Industry Growth | 31.6% |
| Revenue growth rate | 81.9% |
| Return on equity | -1.5% |
| Net Margin | -384.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think Dna Group (T.R.) (TLV:DNA) Can Afford To Drive Business Growth
Apr 12
Dna Group (T.R.) (TLV:DNA) Is In A Strong Position To Grow Its Business
Jul 07We Think Dna Group (T.R.) (TLV:DNA) Can Easily Afford To Drive Business Growth
Jan 24We're Not Worried About D.N.A Biomedical Solutions' (TLV:DNA) Cash Burn
Oct 07Revenue & Expenses BreakdownBeta
How Dna Group (T.R.) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -1 | 2 | 0 |
| 30 Sep 23 | 1 | -4 | 3 | 0 |
| 30 Jun 23 | 1 | -6 | 4 | 0 |
| 31 Mar 23 | 1 | -15 | 5 | 0 |
| 31 Dec 22 | 1 | -24 | 6 | 0 |
| 30 Sep 22 | 0 | -21 | 5 | 0 |
| 30 Jun 22 | 0 | -18 | 4 | 0 |
| 31 Mar 22 | 0 | 0 | 3 | 0 |
| 31 Dec 21 | 0 | 18 | 2 | 0 |
| 30 Sep 21 | 0 | 15 | 2 | 0 |
| 30 Jun 21 | 0 | 12 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -19 | 2 | 0 |
| 30 Sep 20 | 0 | -22 | 2 | 0 |
| 30 Jun 20 | 0 | -25 | 2 | 0 |
| 31 Mar 20 | 0 | -32 | 2 | 0 |
| 31 Dec 19 | 0 | -39 | 2 | 0 |
| 30 Sep 19 | 0 | -27 | 2 | 0 |
| 30 Jun 19 | 0 | -15 | 2 | 0 |
| 31 Mar 19 | 0 | -15 | 2 | 0 |
| 31 Dec 18 | 0 | -14 | 2 | 0 |
| 30 Sep 18 | 0 | -40 | 2 | 0 |
| 30 Jun 18 | 0 | -65 | 2 | 0 |
| 31 Mar 18 | 0 | -60 | 2 | 0 |
| 31 Dec 17 | 0 | -55 | 2 | 0 |
| 30 Sep 17 | 0 | -28 | 0 | -4 |
| 30 Jun 17 | 0 | -13 | 2 | 0 |
| 31 Mar 17 | 0 | -20 | 0 | -2 |
| 31 Dec 16 | 0 | -1 | 2 | 0 |
| 30 Sep 16 | 0 | -10 | 5 | 6 |
| 30 Jun 16 | 0 | -11 | 4 | 4 |
| 31 Mar 16 | 0 | 0 | 8 | 8 |
| 31 Dec 15 | 0 | -1 | 2 | 0 |
| 30 Sep 15 | 0 | -79 | 9 | 7 |
| 30 Jun 15 | 0 | -74 | 8 | 8 |
| 31 Mar 15 | 0 | -74 | 7 | 7 |
| 31 Dec 14 | 0 | -72 | 5 | 7 |
| 30 Sep 14 | 0 | -9 | 4 | 8 |
| 30 Jun 14 | 0 | -9 | 4 | 6 |
| 31 Mar 14 | 0 | -7 | 3 | 5 |
| 31 Dec 13 | 0 | -2 | 3 | 3 |
| 30 Sep 13 | 0 | -2 | 3 | 2 |
Quality Earnings: DNA is currently unprofitable.
Growing Profit Margin: DNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DNA is unprofitable, but has reduced losses over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare DNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNA is unprofitable, making it difficult to compare its past year earnings growth to the Electronic industry (8.9%).
Return on Equity
High ROE: DNA has a negative Return on Equity (-1.49%), as it is currently unprofitable.